NCT04877522 2026-03-06
Asciminib Roll-over Study
Novartis
Phase 4 Recruiting
Clinical Trials
13 trialsNCT05071482 2025-05-01
Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase 4 Terminated
NCT03844360 2025-03-30
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
Shandong University
Phase 4 Recruiting
NCT05367765 2022-05-10
A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 4 Not yet recruiting
NCT02602314 2022-01-20
SUSTRENIM
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 4 Unknown
NCT01578213 2019-12-03
ISAV
University of Milano Bicocca
Phase 4 Completed
NCT02204722 2018-06-15
IDEAL
Dong-A ST Co., Ltd.
Phase 4 Terminated
NCT00171899 2017-02-23
Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)
Novartis
Phase 4 Completed
NCT00845221 2016-10-11
Glivec in Pediatric Chronic Myeloid Leukemia (CML)
Poitiers University Hospital
Phase 4 Completed
NCT02894645 2016-09-30
Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study
National University Hospital, Singapore
Phase 4 Unknown
NCT02317159 2014-12-15
Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia
Cttq
Phase 4 Unknown
NCT00081926 2009-11-23
Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Novartis
Phase 4 Completed
NCT00390897 2008-11-27
Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia
PETHEMA Foundation
Phase 4 Completed